Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies and guidelines: latest news

PrEP policies and guidelines news from aidsmap

More news

PrEP policies and guidelines news selected from other sources

  • My PrEP Story: Will

    As the IMPACT Trial hits its first anniversary, PrEPster co-founder Will Nutland says that the waiting needs to stop: full implementation of PrEP must become a priority.

    12 October 2018 | Prepster
  • UK HIV drugs bill may reduce following court ruling - implications for PrEP

    A ruling today from the European Court of Justice (ECJ) suggests that Gilead’s patent for Truvada (the drug used to treat many people living with HIV, and the drug used for PrEP) may be under threat.

    25 July 2018 | National AIDS Trust
  • Pharma giant withdraws challenge to generic HIV anti-retroviral drug

    Gilead has dropped its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

    21 December 2017 | Irish Times
  • Gilead loss of generic HIV drug battle a boost for gay community

    09 November 2017 | The Irish Times
  • Gilead Continues To Block Ireland From Sourcing Generic Truvada

    Gilead Sciences, the company that supplies Ireland with the drug Truvada, will have a full court hearing in mid-October to determine whether the Irish Health and Safety Executive (HSE) can source a generic analogue of the drug from the pharmaceutical giant’s competitors. In July, GCN reported that Gilead was taking legal action to stop the HSE from securing generic drug from Actavis and Mylan, the company’s competitors, for the purposes of HIV prevention as PrEP.

    16 October 2017 | Gay Community News
  • Generic PrEP in France and Scotland challenges access across the UK

    The issue of drug procurement and pricing is complex but it is difficult to see how different patents should apply within Europe, and especially not within the UK.

    08 September 2017 | HIV i-Base
  • Did HIV Pharma “Pay to Delay” Generic Truvada?

    AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

    04 September 2017 | Poz
  • Mylan to Provide Generic Truvada for U.K. Trial

    The NHS confirmed Thursday that Mylan had won the drug procurement process for a three-year-long implementation trial for pre-exposure prophylaxis, or PrEP, which is used to prevent HIV infection.

    03 August 2017 | Wall Street Journal
  • Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

    The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    07 July 2017 | The Body
  • FDA Approves Generic Truvada for HIV Treatment and PrEP

    In a move that has taken HIV advocates by surprise and stewed considerable confusion, the U.S. Food and Drug Administration (FDA) has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine). This decision could have major implications for the future cost of Truvada, to insurers and consumers alike.

    10 June 2017 | Poz
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.